- KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and after Surgery UroToday
- Pfizer and Astellas announce positive results from phase 3ev-303 clinical trial for Padcev in combination with Keytruda TradingView
- Enfortumab Vedotin Plus Pembro Cuts Risk of Disease Progression, Death 60% for Patients With MIBC Who Can’t Have Chemo With Bladder Removal The American Journal of Managed Care® (AJMC®)
- ESMO25: Padcev, Keytruda regimen given before, after surgery shines in bladder cancer FirstWord Pharma
- KEYNOTE-905: EV/pembrolizumab emerges as new option for cisplatin-ineligible MIBC Urology Times
TL;DR: Bring home a feature-packed MacBook Pro for just $279.97 (reg. $1,499) through Nov. 2, while supplies last.
…
